Ultragenyx Pharmaceutical (RARE) EBITDA Margin Growth (5y) (2021 - 2026)
Ultragenyx Pharmaceutical (RARE) EBITDA Margin Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Ultragenyx Pharmaceutical | 2.72 Bn | 2.31 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,705.00 |
| Dec 31, 2025 | 5,031.00 |
| Sep 30, 2025 | -4,509.00 |
| Jun 30, 2025 | 3,738.00 |
| Mar 31, 2025 | 22,945.00 |
| Dec 31, 2024 | 19,108.00 |
| Sep 30, 2024 | 36,287.00 |
| Jun 30, 2024 | 38,661.00 |
| Mar 31, 2024 | 39,404.00 |
| Dec 31, 2023 | 45,973.00 |
| Sep 30, 2023 | 61,412.00 |
| Jun 30, 2023 | 60,515.00 |
| Mar 31, 2023 | 75,035.00 |
| Dec 31, 2022 | 447,023.00 |
| Sep 30, 2022 | 4.20 Mn |
| Dec 31, 2021 | 141.09 Mn |
| Sep 30, 2021 | 5.92 Mn |
| Jun 30, 2021 | 34.14 Mn |